Efficacy and safety of first-line bevacizumab combined with paclitaxel in 220 patients with metastatic breast cancer: The Hungarian AVAREG observational study

被引：0
|
作者：
Dank, Magdolna
Budi, Laszlo
Landherr, Laszlo
Piko, Bela
Mangel, Laszlo
Erfan, Jozsef
Cseh, Jozsef
Ruzsa, Agnes
Nagy, Andras
机构：
[1] Semmelweis Univ, H-1085 Budapest, Hungary
[2] BAZ Cty Hosp, Miskolc, Hungary
[3] Uzsoki St Hosp, Budapest, Hungary
[4] Bekes Cty Pandy Kalman Hosp, Gyula, Hungary
[5] Univ Pecs, Fac Med, Pecs, Hungary
[6] Josa Andras Oktata Korhaz, Nyiregyhaza, Hungary
[7] Fejer Cty St George Hosp, Szekesfehervar, Hungary
[8] Zala Cty Hosp, Zalaegerszeg, Hungary
[9] Roche Hungary Ltd, Budaors, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12022
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-line Bevacizumab-Paclitaxel in 220 Patients with Metastatic Breast Cancer: Results from the AVAREG Study
    Dank, Magdolna
    Budi, Laszlo
    Piko, Bela
    Mangel, Laszlo
    Erfan, Jozsef
    Cseh, Jozsef
    Ruzsa, Agnes
    Landherr, Laszlo
    ANTICANCER RESEARCH, 2014, 34 (03) : 1275 - 1280
  • [2] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
    Klare, P.
    Foerster, F. G.
    Geberth, M.
    Schneeweiss, A.
    Tesch, H.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [4] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [5] Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France
    Hardy-Bessard, Anne-Claire
    Delva, Remy
    Pivot, Xavier
    Espie, Marc
    Dalenc, Florence
    Sfairi, Marie-Aude Coulon
    Monnier, Alain
    Serin, Daniel
    Veyret, Corinne
    Lortholary, Alain
    Pavlyuk, Maria
    Kockler, Leila
    Pierga, Jean-Yves
    BULLETIN DU CANCER, 2012, 99 (06) : 609 - 618
  • [6] Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer
    Kevin R. Fox
    Current Oncology Reports, 2009, 11 : 5 - 7
  • [7] Adding Bevacizumab to Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer
    Fox, Kevin R.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 5 - 6
  • [8] Bevacizumab Combined with Two-weekly Paclitaxel as First-line Therapy for Metastatic Breast Cancer
    Kountourakis, Panteleimon
    Doufexis, Dimitrios
    Maliou, Savoula
    Karagiannis, Athanasios
    Kardara, Eugenia
    Margari, Charalampia
    Sykoutri, Despoina
    Tzovaras, Alexandros
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2010, 30 (07) : 2969 - 2971
  • [9] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
    Dieras, Veronique
    Pop, Simona
    Berger, Frederique
    Dujaric, Marie-Eglantine
    Beuzeboc, Philippe
    Escalup, Laurence
    Bidard, Francois Clement
    Cottu, Paul Henri
    Le Tourneau, Christophe
    Piperno-Neumann, Sophie
    Laurence, Valerie
    Robain, Mathieu
    Asselain, Bernard
    Pierga, Jean-Yves
    ANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407
  • [10] Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
    Sledge, G.
    Miller, K.
    Moisa, C.
    Gradishar, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345